New targeted therapy daraxonrasib improves survival in pancreatic cancer
1. Daraxonrasib significantly improves survival in metastatic pancreatic cancer compared with standard chemotherapy.
2. Strong response rates in combination therapy suggest broader potential across treatment settings.
Revolution Medicines announced positive topline results from the Phase 3 RASolute 302 trial on April 13, 2026, showing that daraxonrasib nearly doubled survival in previously treated metastatic pancreatic cancer. In the intent to treat population, the RAS(ON) multi selective inhibitor delivered a median overall survival of 13.2 months compared with 6.7 months for standard chemotherapy. That difference stands out in a disease where progress has historically been slow. Updated data presented at the AACR Annual Meeting on April 21 also showed a strong objective response rate when used in combination therapy. These results suggest that the drug may be useful beyond just later line treatment. The consistency of benefit across patient groups has also drawn attention. In pancreatic cancer, even modest improvements are meaningful, which makes these findings especially notable. The therapy appears to have a manageable safety profile based on current data. The company plans to submit these findings to the FDA. Experts at Dana Farber have described this as a meaningful advance for a population with limited treatment options. Ongoing trials are exploring how the drug performs earlier in the disease course. There is also interest in combining it with other targeted therapies. Questions remain about long term durability and real world effectiveness. Even so, the results represent a major step forward in RAS targeted cancer treatment.
Image: PD
©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
